U.S. Specialized REITs Stock News

Kymera Therapeutics stock edged up about 1% to US$105.48 after the Q2 print, a muted move for a biotech reporting US$65m in collaboration revenue and another quarter of sizeable losses. The market seems to be treating this as a steady, low drama update rather than a breakout moment. The key point for investors is the widening gap between a partnership-driven top line and continuing net losses of more than US$60m for the quarter. With cash of about US$1.5b and no more collaboration revenue...

With S&P 500 futures pressing against a key resistance zone and traders watching for either a breakout or a sharp mean reversion, short-term moves in large-cap U.S. stocks are under an intense spotlight. This kind of setup can create sudden winners and sudden laggards, which is why it matters if you care about timing. This article walks through 3 stocks exposed to the current news-driven tension around profit-taking and potential pullbacks. The 3 stocks below are just a starting sample, and...

Boston Scientific (NYSE:BSX) has initiated multiple large-scale recalls of cardiac ablation and access devices affecting hundreds of thousands of units globally in late July and August 2026. An FDA enforcement report cites a software anomaly in the TheraSphere 360 radiological platform, adding to the recent wave of product safety actions. The cluster of recalls and the FDA software enforcement report comes shortly after Boston Scientific's latest earnings and guidance updates. Consider...

With the Federal Reserve debating its next move and markets bracing for the possibility of higher rates, many investors are rethinking how they get reliable income from stocks. Rising borrowing costs and inflation worries can unsettle growth stories, yet they also shine a spotlight on companies that focus on steady dividends and durable cash flows. This article walks through three stocks from a Defensive Dividend Stocks screener that appear positively exposed to the current rate backdrop and...

Douglas Emmett stock slipped 1.3% today to about US$11.80, which is a muted move for a real estate investment trust that just posted another quarter of unprofitable earnings. The emotional drag is clear. Investors are fixating on the reported loss per share and the weight of higher interest costs, while the core real estate engine tells a more balanced story. The real action sits in funds from operations and cash generation. Funds From Operations held in the mid US$70m range in the quarter...

Callaway Golf stock slipped about 2% today, even though the quarter just delivered one of the cleanest margin stories the company has put up in a while. Revenue for Q2 came in at US$612.2m, but the real headline was profit quality, with net income from ongoing operations at US$75.8m and management highlighting a sharp lift in gross margin. Investors came into this print after a strong 90 day run in the stock, so expectations were high. The reaction suggests nerves about sustainability, not...

EVgo stock dropped about 12% to US$1.53 into Thursday, extending a weak 30 day stretch and setting a low bar for this earnings print. The market focused on the red ink, with Q2 2026 delivering a basic loss per share of US$0.15 and net loss of US$20.8m. Looking past the near term pain presents a different picture. Charging network revenue was US$61m, and management is guiding to US$400m to US$430m of revenue for 2026 with an adjusted EBITDA loss that could narrow by year end. This quarter...

Insulet stock just endured a 20% one day hit, sliding from about US$166.82 to roughly US$133.26, even as the latest quarter landed with solid headline strength. The company delivered Q2 revenue of US$801.7 million and basic earnings per share of US$1.37, supported by a trailing P/E of 24.6x that sits below the broader medical equipment peer group. The clash is clear: the tape is trading fear around the new type 2 diabetes rollout and customer retention, while the numbers show a business that...

Clear Secure came into this print with a premium P/E, a soft three month share performance and a reputation as a high growth airport subscription story. The stock is up about 1.3% today, which is a muted response given the headline. Q2 delivered record free cash flow of US$189 million and adjusted EBITDA margin of 36.4%, finally clearing the 35% target management set back at the IPO. For a security and identity platform that investors often treat like a travel tollbooth, this quarter is...

Amgen just added roughly 5% in market value in a single session, with the stock jumping to about US$408, and the move tracks a quarter that gave investors something concrete to latch onto. Q2 revenue crossed US$10b and basic earnings per share landed above US$4. The bigger story sits on a longer time frame. Trailing 12 month earnings are now above US$16 per share and management has lifted full year guidance, which keeps the focus on whether this earnings run can support a valuation that still...

Traders pushed American Financial Group up about 4% to US$146.73 today after its Q2 report, rewarding a quarter that delivered punchy profitability rather than flashy top line growth. Core net operating earnings reached US$2.82 per share and property and casualty underwriting generated a Q2 record for pre tax operating income, with a specialty insurance combined ratio of 91.5%. Those are short term headlines. The bigger story for long term holders is that profit margins and return on equity...

Northeast Bank recently reported past fourth-quarter results for the period ended June 30, 2026, with net interest income rising to US$60.32 million and net income reaching US$34.34 million, alongside slightly higher net charge-offs of US$1.80 million and a cash dividend declaration of US$0.01 per share. The sharp year-over-year increase in earnings per share from continuing operations, even as charge-offs inched higher, highlights how stronger core lending profitability has supported...

Geron stock jumped 21.6% to US$1.63 on the first trading day after its Q2 release, a sharp move for a company long viewed as a discounted oncology developer with a long road to profitability. The headline is simple: solid revenue traction from RYTELO and stable operating spend have pulled losses into a narrower band, while the balance sheet still carries US$327m of cash. For a stock that came into earnings with modest double digit gains over 1, 3 and 6 months, this report has turned what was...

SpaceX has just shocked the market by pouring $18.4b into AI projects, with spending far beyond its recent revenue jump and sending the stock sharply lower. That kind of aggressive move can reshuffle where capital flows across the wider AI infrastructure space. This article walks through 3 stocks exposed to this news, explaining how they might be affected by the surge in cloud and compute demand and outlining where key risks could sit. The stocks covered below are just a starting sample from...

CorVel’s stock jumped 5.9% to US$62.57 into the close, which indicates traders responded positively to the results. The key point is that the earnings beat was meaningful. Revenue reached about US$259.9m and basic earnings per share came in near US$0.63, with the quarter supported by strong performance in payment integrity and broader workers’ compensation services. CorVel entered this report with mixed short-term returns but a solid earnings track record and a valuation that already sat...

Hudson Pacific Properties stock jumped 7.1% to US$14.97 after the Q2 release, a sharp move for a company that came into today with a flat week and a tough recent track record. The headline was not earnings per share. The market latched on to a different story. Core funds from operations, or core FFO, nearly tripled to US$23.1 million and management nudged full year core FFO guidance higher. The short term price pop is about relief and renewed confidence. The bigger question for you is whether...

Ultragenyx Pharmaceutical stock slipped 3.4% to about US$24.93 as investors digested a fresh set of numbers that mixed record sales with continued losses. Q2 revenue reached US$214m, led by rare disease drugs such as Crysvita, while the company still reported a net loss of US$92m, or US$0.90 per share. For traders focused on this week, that loss keeps the pressure on. For investors thinking in years rather than days, the key points are the record top line, the active late stage pipeline and...

Guardant Health stock has delivered very strong returns over the past few years, yet the signals on what that means for valuation are mixed, with the Discounted Cash Flow (DCF) intrinsic value estimate pointing to upside while market multiples suggest the shares screen expensive. Guardant Health has returned 347.6% over the past three years, which puts extra focus on whether the current share price leaves much margin for error. Growing adoption of the Guardant360 and Shield blood tests may...

FRP Holdings stock slipped 2.4% to US$21.93 after its Q2 report, yet the real story sits in a different place than the share chart. The headline this quarter is a squeeze on profitability. Trailing net profit margin has compressed to 0.3% compared with 16.5% a year earlier, and reported earnings over the past five years have retreated at an average rate of 45.8% a year. Investors are reacting to that margin picture more than to the solid real estate platform or cash on hand. The question now...

Marqeta stock just handed investors a 7% one day drop, yet the earnings story leans far more toward a profitability grind than a collapse. Coming into the print, the stock had been roughly flat over three months, with only a small gain over 30 days. Then the market met a payments platform that printed about US$176m in Q2 net revenue and roughly US$8m in net income, its second straight profitable quarter. The real headline is margin power. Adjusted earnings before interest, tax, depreciation...

Louisiana-Pacific stock barely budged after earnings, up just 0.7% to US$77.36, yet the quarter itself was anything but quiet. The company posted Q2 2026 revenue of US$664m and basic earnings per share of US$0.37, with investors weighing those construction cycle exposed numbers against a rich trailing P/E of about 100x. The real story for you is the squeeze between modest profits and a high multiple, especially with trailing net profit margin running at 2.2% and a recent one off loss still...

Zeta Global Holdings went into this earnings print as a high growth marketing and AI platform stock with a loyal bull camp and a lot to prove on profitability. The market liked what it saw. The share price jumped 11.6% to US$27.07 after the release, extending a strong three month run. The headline this quarter is profit. Zeta Global Holdings shifted from a loss in Q1 to GAAP net income of US$8.2 million, with basic earnings per share of US$0.03, on revenue of US$442.8 million. That move into...

Healthpeak Properties stock barely budged, up less than 1% to around US$21.79, even though the earnings story was all about stronger cash generation. For a real estate investment trust, funds from operations is what matters, and Healthpeak reported adjusted funds from operations of US$0.46 per share in the quarter with total revenue of US$771.6m. The market reaction looks muted compared with that core cash figure and a raised full year adjusted funds from operations guidance range. Investors...

Banc of California, Inc. reported second-quarter 2026 results showing net interest income of US$250.5 million but a net loss of US$241.35 million, a reversal from net income a year earlier, alongside basic and diluted losses per share of US$1.61 from continuing operations. The quarter also saw net charge-offs surge to US$160,281,000 from US$44,222,000 a year ago, highlighting a sharp deterioration in credit costs even as management emphasized balance sheet repositioning efforts. We’ll now...